{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:18:46Z","timestamp":1788826726832,"version":"build-2803163510"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005107","name":"Australasian Blistering Diseases Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005107","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jdcr.2024.12.014","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:13:12Z","timestamp":1735258392000},"page":"98-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Severe case of bullous pemphigoid associated with nivolumab responsive to combination therapy with dupilumab and omalizumab"],"prefix":"10.1016","volume":"57","author":[{"given":"Liana","family":"Victory","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Quigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Bowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cliona","family":"Feighery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Fortune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdcr.2024.12.014_bib1","article-title":"Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.jdcr.2024.12.014_bib2","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.3390\/jcm11123367","article-title":"Use of dupilumab in bullous pemphigoid: where are we now?","volume":"11","author":"Russo","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.jdcr.2024.12.014_bib3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jdcr.2020.01.002","article-title":"Increasing evidence for omalizumab in the treatment of bullous pemphigoid","volume":"6","author":"Lonowski","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jdcr.2024.12.014_bib4","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2024.12.014_bib5","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.jdcr.2024.12.014_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D327955136","article-title":"Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature","volume":"27","author":"Klepper","year":"2021","journal-title":"Dermatol Online J"},{"issue":"3","key":"10.1016\/j.jdcr.2024.12.014_bib7","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaci.2008.11.035","article-title":"Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab","volume":"123","author":"Fairley","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jdcr.2024.12.014_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.611549","article-title":"Case report: combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid","volume":"11","author":"Seyed Jafari","year":"2021","journal-title":"Front Immunol"},{"issue":"Supplement_2","key":"10.1016\/j.jdcr.2024.12.014_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljac140.007","article-title":"307 The study design of a trial of dupilumab in adult patients with bullous pemphigoid (BP): LIBERTY-BP ADEPT","volume":"188","author":"Murrell","year":"2023","journal-title":"Br J Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624005058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624005058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T16:41:22Z","timestamp":1742229682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512624005058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":9,"alternative-id":["S2352512624005058"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.12.014","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe case of bullous pemphigoid associated with nivolumab responsive to combination therapy with dupilumab and omalizumab","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}